HOLLIS-EDEN PHARMACEUTICALS
Hollis-Eden Pharmaceuticals is focused on research and development of adrenal steroid hormones as pharmaceuticals for human health. Hollis-Eden Pharmaceuticals offers a hormonal signaling technology platform that develops small molecule compounds. The company offers TRIOLEX, a treatment for type 2 diabetes; and APOPTONE, a treatment for cancer. Hollis-Eden Pharmaceuticals was founded by Richard B. Hollis.
Similar Organizations
Berk Pharmaceutical
Berk Pharmaceutical is a Pharmaceuticals company.
Founder
More informations about "Hollis-Eden Pharmaceuticals"
Hollis-Eden Pharmaceuticals - Crunchbase Company …
Hollis-Eden Pharmaceuticals is focused on research and development of adrenal steroid hormones as pharmaceuticals for human health. Hollis-Eden …See details»
Richard B. Hollis - Wikipedia
Richard B. Hollis is an American businessman. He is the founder, chairman, and CEO of Holonis, Inc., a San Diego–based software company. Hollis had previously founded Hollis-Eden Pharmaceuticals, a San Diego–based pharmaceutical company, in 1994. See details»
Hollis-Eden Announces Name Change to Harbor BioSciences, Inc.
Feb 17, 2010 /PRNewswire-FirstCall/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), today announced that it has changed its name to Harbor BioSciences, Inc. and that...See details»
Hollis-Eden Pharmaceuticals 2002 Annual Report
IRH technology, Hollis-Eden is passionately driven with a consistency of purpose: to serve humanity by converting our technology into products strategicall positioned to play a major role …See details»
Hollis-Eden Pharmaceuticals - LinkedIn
Hollis-Eden Pharmaceuticals | 209 followers on LinkedIn.See details»
Hollis-Eden Pharmaceuticals, Inc. - San Diego, USA - bionity.com
Aug 7, 2008 Hollis-Eden Pharmaceuticals, Inc. is a world leader in the development of a proprietary class of adrenal steroid hormones as novel pharmaceuticals for human health. …See details»
HOLLIS EDEN PHARMACEUTICALS INC /DE/ (Form: 10-K, Filing …
HOLLIS EDEN PHARMACEUTICALS INC /DE/ CIK:899394| IRS No.: 133697002 | State of Incorp.:DE | Fiscal Year End: 1231 ... of incorporation or organization) (I.R.S. Employer …See details»
Hollis Eden Pharmaceuticals - Drug pipelines, Patents, Clinical trials ...
Explore Hollis Eden Pharmaceuticals with its drug pipeline, therapeutic area, technology platform, 1 news, and 8 literature, Drug:HE-2100, IDPS, HE-2200, Immunitin.See details»
Press Release: Hollis-Eden Pharmaceuticals Announces …
Apr 27, 2007 Hollis-Eden Pharmaceuticals Announces Reorganization; to Cut Headcount by 25% SAN DIEGO -- Hollis-Eden Pharmaceuticals, Inc. today announced a restructuring …See details»
Hollis-Eden Pharmaceuticals Inc., Richard B. Hollis,
Hollis-Eden Pharmaceuticals Inc. Ticker Symbol: HEPH: Address: 4435 Egate Mall Ste. 400 San Diego, CA 92121 ...See details»
HOLLIS-EDEN PHARMACEUTICALS, INC. - getfilings.com
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12See details»
Hollis Eden Pharmaceuticals (Hollis Eden Pharmaceuticals) - 药物 …
了解Hollis Eden Pharmaceuticals (Hollis Eden Pharmaceuticals)公司的药物管线，治疗领域，技术平台，以及它的1篇新闻和8篇文献，药物:HE-2100，IDPS，HE-2200，Immunitin。See details»
PROHIVITAC - Hollis-Eden Pharmaceuticals, Inc. Trademark …
Hollis-Eden Pharmaceuticals, Inc. USPTO Trademarks › Hollis-Eden Pharmaceuticals, Inc. › Prohivitac Application #75799822. Application Filed: 1999-09-14. Trademark Application …See details»
Hollis-Eden Licenses Technology To Augment Hormone Program
Aug 30, 2002 Hollis-Eden Pharmaceuticals Inc. licensed certain intellectual property from Pharmadigm Inc. and the University of Utah to use in its program of hormonal regulation of …See details»
Hollis, Richard B. - The Wall Street Transcript
Nov 17, 2008 RICHARD B. HOLLIS founded Hollis-Eden Pharmaceuticals, Inc., in August 1994, and currently serves as Chairman, President and Chief Executive Officer. Mr. Hollis has over …See details»
HOLLIS-EDEN PHARMACEUTICALS TO RAISE $26.0 MILLION
SAN DIEGO – February 2, 2006 — Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) today announced that it has entered into definitive agreements to raise $26.0 million in gross …See details»
BioCentury - Hollis-Eden management update
Mar 8, 1999 Hollis-Eden Pharmaceuticals Inc. (HEPH), San Diego, Calif. Business: Infectious diseases Resigned: Terren Peizer as president, vice chairman and a director... This Edition. …See details»
John Healy Appointed General Counsel & Corporate Secretary at …
Prior to his consulting practice, Mr. Healy served as General Counsel & Secretary for Hollis-Eden Pharmaceuticals, a publicly traded biotechnology company. Mr. Healy began his career …See details»
PRESS RELEASE: Hollis-Eden Pharmaceuticals Presents HE3235 …
Sep 7, 2007 SAN DIEGO -- Hollis-Eden Pharmaceuticals, the leader in the development of a new class of small molecule compounds based on endogenous steroid hormones, today …See details»
Hollis-Eden reports promising results for multiple sclerosis treatment
Hollis-Eden Pharmaceuticals has announced new data showing that its pre-clinical drug candidate provides benefit in an animal model of multiple sclerosis. The company is planning to present …See details»